Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.84 |
| ▸ | SLC5A1 | P13866 | 14/20 | 0.84 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4359344 | 1.00 | SLC5A2 (0.84) | SLC5A2SLC5A1TYMP | |
| SCHEMBL4351206 | 0.94 | SLC5A2 (0.84) | SLC5A2SLC5A1TYMP | |
| SCHEMBL4351209 | 0.94 | SLC5A2 (0.84) | SLC5A2SLC5A1TYMP | |
| SCHEMBL4006195 | 0.92 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL4006197 | 0.92 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL14648452 | 0.92 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL4361433 | 0.92 | SLC5A2 (0.75) | SLC5A2SLC5A1TYMP | |
| SCHEMBL4361439 | 0.92 | SLC5A2 (0.75) | SLC5A2SLC5A1TYMP | |
| Sergliflozin Etabonate SCHEMBL23731198 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| Sergliflozin Etabonate SCHEMBL621807 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333353-A1 | BILAYER TABLET FORMULATIONS | BRISTOL-MEYERS SQUIBB COMPANY | 2017-11-23 | — | — | US | disclosed |
| US-9616028-B2 | Bilayer tablet formulations | ASTRAZENECA AB (SE) | 2017-04-11 | — | — | US | disclosed |
| EP-1782828-B1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-20150238421-A1 | Bilayer Tablet Formulations | ASTRAZENECA AB (SE) | 2015-08-27 | — | — | US | disclosed |
| US-9050258-B2 | Bilayer tablet formulations | ASTRAZENECA AB (SE) | 2015-06-09 | — | — | US | disclosed |
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140335170-A1 | Reduced Mass Metformin Formulations | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-13 | — | — | US | disclosed |
| US-8871264-B2 | Immediate release tablet formulations | ASTRAZENECA AB (SE) | 2014-10-28 | — | — | US | disclosed |
| US-20140079778-A1 | Pharmaceutical Formulations Including An Amine Compound | ASTRAZENECA UK LIMITED (GB) | 2014-03-20 | — | — | US | disclosed |
| US-8535715-B2 | Bilayer tablet formulations | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130224296-A1 | Drug Formulations Using Water Soluble Antioxidants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130034606-A1 | IMMEDIATE RELEASE TABLET FORMULATIONS | ASTRAZENECA UK LIMITED (GB) | 2013-02-07 | — | — | US | disclosed |
| US-20120294936-A1 | REDUCED MASS METFORMIN FORMULATIONS | ASTRAZENECA UK LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| US-20120282336-A1 | BILAYER TABLET FORMULATIONS | ASTRAZENECA UK LIMITED (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1782828-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333353-A1 | BILAYER TABLET FORMULATIONS | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885TYMP 3625/4885 |
| US-20150238421-A1 | Bilayer Tablet Formulations | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885TYMP 3625/4885 |
| US-20130034606-A1 | IMMEDIATE RELEASE TABLET FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | SLC5A2 1/4885SLC5A1 2/4885TYMP 3076/4885 |
| US-20140335170-A1 | Reduced Mass Metformin Formulations | GLP1R, SLC5A2, GCKR | SLC5A2 2/4885SLC5A1 9/4885TYMP 1080/4885 |
| US-20140079778-A1 | Pharmaceutical Formulations Including An Amine Compound | CFD, FPR1, F12 | SLC5A2 1966/4885SLC5A1 1593/4885TYMP 2354/4885 |
| US-20130224296-A1 | Drug Formulations Using Water Soluble Antioxidants | NQO1, FPGS, CFD | SLC5A2 1533/4885SLC5A1 1393/4885TYMP 1845/4885 |
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | SLC10A1, SLC2A2, SLC2A1 | SLC5A2 10/4885SLC5A1 12/4885TYMP 3589/4885 |
| US-20120282336-A1 | BILAYER TABLET FORMULATIONS | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885TYMP 3625/4885 |
| US-20120294936-A1 | REDUCED MASS METFORMIN FORMULATIONS | GLP1R, SLC5A2, GCKR | SLC5A2 2/4885SLC5A1 9/4885TYMP 1080/4885 |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | FABP1, SLC2A1, SLC10A1 | SLC5A2 11/4885SLC5A1 15/4885TYMP 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.